To include your compound in the COVID-19 Resource Center, submit it here.

Mavupharma raises 20M in series A round for STING modulators

Mavupharma Inc. (Kirkland, Wash.) raised $20 million in a series A round led by Frazier Healthcare Partners. Alpine BioVentures also participated.

Mavupharma is developing orally bioavailable, non-nucleotide agonists

Read the full 278 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE